| Revenue Growth | Revenue increased $1.5 million YoY to $5.2 million from license revenue. |
|---|---|
| Mgmt Confidence | High confidence in AMT-130 data showing 75% slowing of disease progression. |
| Demand Visibility | Expect uptake shaped by treatment center capacity, not patient demand. |
| Margin Trends | R&D expenses increased $1.1 million; SG&A increased $4.5 million for launch. |
| Op. Leverage | Disciplined build-out of field teams ahead of 2027 potential launch. |
| Pricing Power | Engaging payers on economic profile of one-time gene therapy. |
| Segment Growth | AMT-130 high-dose showed 60% slowing on Total Functional Capacity. |
| New Clients | Identifying priority treatment centers in the U.S. and U.K. |
| Capex & Debt | Cash and investments of $768.4 million as of September 30, 2026. |
| Regulatory | FDA priority review granted; PDUFA May 1, 2027; MHRA application validated. |
| Commentary | Focusing on Total Functional Capacity as the most clinically meaningful endpoint. |
| New Launches | Planned U.S. launch of AMT-130 in 2027; confirmatory study starting 2026. |
Growth
Q3 2026 revenue rose to $5.2 million from $3.7 million in 2025.
Outlook
Cash runway sufficient into 2030; AMT-130 PDUFA date set for May 1, 2027.
Risks
Management was evasive regarding FDA Day 74 letter contents and potential AdCom timing.
The company's earnings call, NASDAQ: QURE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
uniQure N.V.: key numbers
- Share price
- $21.88Close, Nov 16
- Market cap
- $1.53B
- Shares outstanding
- 70.14MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from uniQure N.V.
All →uniQure Insider David D. Meek Sells $193K of Stock
David D. Meek sold 9,080 shares of uniQure N.V. at $21.25 a share, worth $193K in total on Nov 6, 2026. Shares held after the trade: 30,667 (-22.8%).
- Value
- $193K
- Shares
- 9,080
- Price
- $21.25
- Holding change
- -22.8%
- Trade date
- Nov 6, 2026
uniQure Q3 2026 Results: Net Loss of $61.2M, Loss Narrows
For the nine months ended September 30, 2026, uniQure N.V. reported a net loss of $195.8 million, an increase from the $161.9 million loss in the prior year period. Total assets grew to $940.6 million, supported by a follow-on public offering and the exercise of pre-funded warrants which contributed to a significant increase in additional paid-in capital.
- Key figure
- Net loss $61.2M
uniQure Financial Results
uniQure reported Q3 2026 financial results, highlighting a cash position of $768.4 million which is expected to fund operations into 2030. The company also announced that the FDA has granted Priority Review for its BLA for AMT-130 in Huntington’s disease with a PDUFA date of May 1, 2027.
“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease. We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”
Matthew Kapusta, chief executive officer at uniQure
“As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.”
Matthew Kapusta, chief executive officer at uniQure
uniQure Business Update
uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease, for review under the Accelerated Approval pathway. The FDA granted the application Priority Review with a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting to discuss the application.
- Counterparty
- FDA
uniQure Clinical Trial Data
uniQure N.V. released a clinical program update for AMT-130 (ifezuntirgene inilparvovec), its gene therapy candidate for Huntington’s disease. The update includes long-term data from ongoing Phase I/II clinical trials and details regarding the enrollment of a fourth cohort. The company is also evaluating neurofilament light chain (NfL) in cerebrospinal fluid as a potential biomarker for disease severity.